Patient assistance nonprofit contacted in Aegerion probe; most heavily marketed drugs in Canada offer little therapeutic value; the FDA pans Duchenne drug
Five things for pharma marketers to know: Wednesday, September 13, 2017
Merck CEO Kenneth Frazier’s exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.
Five things for pharma marketers to know: Thursday, August 31, 2017
Pfizer develops Minecraft version for kids with hemophilia; Lilly to resubmit baricitinib to the FDA; pricing expert says Novartis CAR-T value contract is ‘progress’
Five things for pharma marketers to know: Wednesday, August 30, 2017
Nonprofits receive FDA approval for Chagas drug; Gilead’s buyout of Kite will put it back in pricing fray; most cancer patients don’t receive fertility info
Five things for pharma marketers to know: Wednesday, August 23, 2017
Doctors fret about price of Novartis’ experimental CAR-T therapy; study finds digital pillboxes don’t improve adherence; India awards Pfizer vaccine patent
Five things for pharma marketers to know: Friday, August 18, 2017
Gottlieb criticizes drugmakers for ‘gaming the system’ on generics; investors ignore Trump’s pharma criticism; docs are more supportive of single payer
Frazier’s call earns him praise, rare for a pharma CEO